Skip to content
sellWeak cluster of 1110b5-1 plan

Mark E. Bunnage sold $302k of VRTX

EVP, Chief Scientific Officer at VERTEX PHARMACEUTICALS INC / MA. 620 shares at an average of $486.35, traded Feb 25, 2026, filed Feb 26, 2026.

Warning score
24
Value
$302k
620 shares
Holdings after
7,284
-8% from before
From 52-week low
+32%
low $366.54, close $483.05
From 52-week high
-6%
high $513.76, as of Feb 25, 2026

Score components

  • Role
    Officer
    +15
  • Trade size
    $302k at market
    +14
  • Share of holdings sold
    Sold 7.8% of holdings
    0
  • Cluster
    11 insiders selling within 14 days
    +15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -9.8%, 3m -6.7%, 6m +14.0%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

VRTXOct 9, 2026 · close 510.08
Since filing Feb 26, 2026: +6.2%SPY +13.8% · excess -7.5%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000875320-26-000112, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Feb 24, 2026FTax withholding
Common Stock10b5-1
-582$485.11$282k7,904Feb 26, 2026
Feb 25, 2026SOpen-market sale
Common Stock10b5-1
-620$486.35$302k7,284Feb 26, 2026

Related signals

Other insiders at VERTEX PHARMACEUTICALS INC / MA and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
37Weak
VRTXsell 410b5-1
VERTEX PHARMACEUTICALS INC / MA
Duncan McKechnie
EVP, Chief Commercial Officer
$800k
1,541 shares
-12%
32Weak
VRTXsell 410b5-1
VERTEX PHARMACEUTICALS INC / MA
Ourania Tatsis
EVP, Chief Reg. & Quality Off.
$787k
1,500 shares
-3%
26Weak
VRTXsell 410b5-1
VERTEX PHARMACEUTICALS INC / MA
Joy Liu
EVP and Chief Legal Officer
$416k
828 shares
-4%
24Weak
VRTXsell 410b5-1
VERTEX PHARMACEUTICALS INC / MA
Carmen Bozic
EVP and CMO
$288k
596 shares
-4%
27Weak
VRTXsell 410b5-1
VERTEX PHARMACEUTICALS INC / MA
Carmen Bozic
EVP and CMO
$471k
1,020 shares
-6%
33Weak
VRTXsell 210b5-1
VERTEX PHARMACEUTICALS INC / MA
Carmen Bozic
EVP and CMO
$1.8M
4,062 shares
-19%
25Weak
VRTXsell 210b5-1
VERTEX PHARMACEUTICALS INC / MA
Carmen Bozic
EVP and CMO
$785k
1,745 shares
-8%
18Weak
VRTXsell 210b5-1
VERTEX PHARMACEUTICALS INC / MA
Joy Liu
EVP and Chief Legal Officer
$364k
828 shares
-4%
33Weak
VRTXsell 310b5-1
VERTEX PHARMACEUTICALS INC / MA
Carmen Bozic
EVP and CMO
$888k
1,974 shares
-8%
30Weak
VRTXsell 410b5-1
VERTEX PHARMACEUTICALS INC / MA
Carmen Bozic
EVP and CMO
$614k
1,354 shares
-5%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Mark E. Bunnage sold $302k of VRTX | InsiderTell